NCT01870401已完成不适用
A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries(Lutonix BTK Trial)
C. R. Bard100 个研究点 分布在 8 个国家目标入组 442 人开始时间: 2013年6月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 442
- 试验地点
- 100
- 主要终点
- Number of Participants With Freedom From Below-the-Knee (BTK) Major Adverse Limb Event and Peri-Operative Death (POD) at 30 Days Post Index Procedure.
研究概览
简要总结
To assess the safety and efficacy of the Lutonix Drug Coated Balloon (DCB) for treatment of stenosis or occlusion of native below-the-knee arteries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant female ≥18 years of age;
- •Rutherford Clinical Category 3, 4 & 5;
- •Life expectancy ≥ 1 year;
- •Significant stenosis (≥70%)
- •A patent inflow artery;
- •Target vessel(s) diameter between 2 and 4 mm;
- •Target vessel(s) reconstitute(s) at or above the ankle
排除标准
- •Pregnant or planning on becoming pregnant;
- •History of stroke within 3 months;
- •History of MI, thrombolysis or angina within 30 days of enrollment;
- •Planned major amputation (of either leg)
- •Prior major amputation if amputation occurred less than one year prior to enrollment and if patient is not independently ambulating;
- •GFR ≤ 30 ml/min per 1.73m2;
- •Acute limb ischemia;
- •In-stent restenosis of target lesion
结局指标
主要结局
Number of Participants With Freedom From Below-the-Knee (BTK) Major Adverse Limb Event and Peri-Operative Death (POD) at 30 Days Post Index Procedure.
时间窗: 30 days post index procedure
The primary safety endpoint is defined as freedom from the composite of all-cause death, above-ankle amputation or major reintervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis) of the index limb involving a below-the-knee artery.
Number of Participants With Freedom From the Composite of Above-ankle Amputation, Target Lesion Occlusion, and Clinically-driven Target Lesion Revascularization at 6 Months Post Index Procedure.
时间窗: 6 months post-index procedure
The primary efficacy endpoint is defined as freedom from the composite of above-ankle amputation, target lesion occlusion, and clinically-driven target lesion revascularization. All amputations included in endpoints refer to amputations in the index limb.
次要结局
- Percentage of Procedures With Procedural Success at Time of Index Procedure.(At time of Index Procedure)
- Change in European Quality of Life 5 Dimensions (EuroQol -5D) Scores at 30 Days, 6 and 12 Months Compared to Baseline.(30 days, 6 and 12 months post index procedure compared to baseline)
- Late Lumen Loss at 12 Months Post Index Procedure(12 months post-index procedure)
- Percentage of Existing, New, and Recurrent Wounds at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Percentage of Participants With Freedom From Primary Patency Failure at 30 Days, 6 and 12 Months Post Index Procedure(30 days and at 6 and 12 months)
- Percentage of Lesions Considered Technical Success at Time of Index Procedure(At time of index procedure)
- Comparison of the Below the Knee (BTK) Major Adverse Limb Event (MALE) and Perioperative Death (POD) Rate to a Performance Goal at 30 Days Post Index Procedure.(30 days post index procedure)
- Number of Healed Wounds at 30 Days, 6 and 12 Months Post Index Procedure(30 days, 6 and 12 months post index procedure)
- Change in Rutherford Classification Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.(30 days, 6 and 12 months post index procedure compared to baseline)
- Percentage of Lesions With Primary Patency Excluding Early Mechanical Recoil at 30 Days, 6 and 12 Months Post Index Procedure(30 days, 6 and 12 months post index procedure)
- Number of Non-Healed Wounds by Category (Improving, Stagnant and Worsening) at 30 Days, 6 and 12 Months Post-Index Procedure.(30 days, 6 and 12 months post index procedure)
- Number of Lesions With Secondary Patency at 30 Days, 6 and 12 Months Post Index Procedure(30 days, 6 and 12 months post index procedure)
- Change in Toe Brachial Index (TBI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline(30 days, 6 and 12 months post index procedure compared to baseline)
- Number of Participants With Freedom From Above Ankle Amputation, Unhealed Wound, Ischemic Rest Pain, Target Vessel Occlusion, and Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Composite of Freedom From Clinically -Driven Target Lesion Revascularization (TLR) and From 50% DS by Angiography or Duplex Ultrasound at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Change in Walking Impairment Questionnaire (WIQ) Scores at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline.(30 days, 6 and 12 months post index procedure compared to baseline)
- Number of Participants With Clinically-Driven Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure(30 days, 6 and 12 months post index procedure)
- Change in Ankle Brachial Index (ABI) at 30 Days, 6 and 12 Months Post Index Procedure Compared to Baseline(30 days, and at 6 and 12 months compared to baseline)
- Cumulative Number of Target Lesion Revascularization (TLR) at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Number of Participants With Clinically-Driven Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Cumulative Number of Target Vessel Revascularization (TVR) at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Percentage of Participants With Freedom From Limb Amputation at 30 Days, 6 and 12 Months Post Index Procedure(30 days and at 6 and 12 months)
- Percentage of Participants With Freedom From Unplanned Below the Knee (BTK) Amputation of the Target Limb at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Cumulative Number of of Below the Knee (BTK) Index-Limb Reinterventions at 30 Days, 6 and 12 Months Post Index Procedure.(30 days, 6 and 12 months post index procedure)
- Percentage of Participants With Freedom From Composite of Perioperative Death (POD), Index Limb-related Death, Below the Knee Reinterventions or Major Amputations of the Index Limb at 30 Days, 6 and 12 Months Post Index Procedure(30 days, 6 and 12 months post index procedure)
研究者
研究点 (100)
Loading locations...
相似试验
已完成
不适用
Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent RestenosisFemoral Artery StenosisFemoral Artery OcclusionRestenosisNCT02063672C. R. Bard82
已完成
不适用
A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal ArteriesFemoral Artery StenosisFemoral Artery OcclusionStenosis of Popliteal ArteriesOcclusion of Popliteal ArteriesNCT02720003C. R. Bard148
已完成
1 期
LEVANT I, The Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal RestenosisVascular DiseaseAtherosclerosisArteriosclerosisNCT00930813C. R. Bard101
Unknown
不适用
Long-term Efficacy of Drug-coated Balloon Versus Drug-eluting Stent in Large de Novo Coronary LesionsDrug-coated BalloonCoronary Artery DiseaseNCT05101005Lepu Medical Technology (Beijing) Co., Ltd.400
已完成
不适用
Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal ArteriesFemoral Artery OcclusionFemoral Arterial StenosisNCT02013271C. R. Bard125